Linked Life Data

15541874

Source:http://linkedlifedata.com/resource/pubmed/id/15541874

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15541874rdf:typepubmed:Citationlld:pubmed
pubmed-article:15541874lifeskim:mentionsumls-concept:C0021289lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0700597lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C1882598lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0003467lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0079925lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C1136031lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0597360lld:lifeskim
pubmed-article:15541874lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:15541874pubmed:issue3lld:pubmed
pubmed-article:15541874pubmed:dateCreated2004-11-15lld:pubmed
pubmed-article:15541874pubmed:abstractTextBrain alpha2-adrenergic receptors (alpha2-ARs) have been implicated in the regulation of anxiety, which is associated with stress. Environmental treatments during neonatal development could modulate the level of brain alpha2-AR expression and alter anxiety in adults, suggesting possible involvement of these receptors in early-life programming of anxiety state. The present study was undertaken to determine whether the reduction of the expression of A subtype of these receptors most abundant in the neonatal brain affects anxiety-related behavior in adulthood. We attenuated the expression of alpha2A-ARs during neonatal life by two different sequence specific approaches, antisense technology and RNA interference. Treatment of rats with the antisense oligodeoxynucleotide or short interfering RNA (siRNA) against alpha2A-ARs on the days 2-4 of their life, produced a marked acute decrease in the levels of both alpha2A-AR mRNA and [3H]RX821002 binding sites in the brainstem into which drugs were injected. The decrease of alpha2A-AR expression in the neonatal brainstem influenced the development of this receptor system in the brain regions as evidenced by the increased number of [3H]RX821002 binding sites in the hypothalamus of adult animals with both neonatal alpha2A-AR knockdown treatments; also in the frontal cortex of antisense-treated, and in the hippocampus of siRNA-treated adult rats. These adult animals also demonstrated a decreased anxiety in the elevated plus-maze as evidenced by an increased number of the open arm entries, greater proportion of time spent in the open arms, and more than a two-fold increase in the number of exploratory head dips. The results provide the first evidence that the reduction in the brain expression of a gene encoding for alpha2A-AR during neonatal life led to the long-term neurochemical and behavioral alterations. The data suggests that alterations in the expression of the receptor-specific gene during critical periods of brain development may be involved in early-life programming of anxiety-related behavior.lld:pubmed
pubmed-article:15541874pubmed:languageenglld:pubmed
pubmed-article:15541874pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:citationSubsetIMlld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15541874pubmed:statusMEDLINElld:pubmed
pubmed-article:15541874pubmed:issn0306-4522lld:pubmed
pubmed-article:15541874pubmed:authorpubmed-author:ShishkinaG...lld:pubmed
pubmed-article:15541874pubmed:authorpubmed-author:DygaloN NNNlld:pubmed
pubmed-article:15541874pubmed:authorpubmed-author:KalininaT STSlld:pubmed
pubmed-article:15541874pubmed:issnTypePrintlld:pubmed
pubmed-article:15541874pubmed:volume129lld:pubmed
pubmed-article:15541874pubmed:ownerNLMlld:pubmed
pubmed-article:15541874pubmed:authorsCompleteYlld:pubmed
pubmed-article:15541874pubmed:pagination521-8lld:pubmed
pubmed-article:15541874pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:meshHeadingpubmed-meshheading:15541874...lld:pubmed
pubmed-article:15541874pubmed:year2004lld:pubmed
pubmed-article:15541874pubmed:articleTitleAttenuation of alpha2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood.lld:pubmed
pubmed-article:15541874pubmed:affiliationInstitute of Cytology and Genetics, Lavrentjev Av. 10, Novosibirsk 630090, Russia.lld:pubmed
pubmed-article:15541874pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15541874pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:15541874pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15541874lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15541874lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15541874lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15541874lld:pubmed